Annual Revenue
N/A
01 December 2023
Summary:
Plus Therapeutics annual revenue is not available.PSTV Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
N/A
01 September 2024
Summary:
Plus Therapeutics quarterly revenue is not available.PSTV Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
N/A
01 September 2024
Summary:
Plus Therapeutics TTM revenue is not available.PSTV TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
PSTV Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time |
Plus Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $303.00 K(-95.7%) | - | - |
| June 2020 | - | $185.00 K(+56.8%) | $6.26 M(+3.0%) |
| Mar 2020 | - | $118.00 K(-90.1%) | $6.08 M(-9.2%) |
| Dec 2019 | $7.00 M(+134.6%) | $1.19 M(-75.1%) | $6.70 M(-21.1%) |
| Sept 2019 | - | $4.77 M(+547.4%) | $8.49 M(+60.8%) |
| Mar 2019 | - | $737.00 K(-75.3%) | $5.28 M(-14.7%) |
| Dec 2018 | $2.98 M(-53.5%) | $2.98 M(+91.3%) | $6.19 M(-4.9%) |
| June 2018 | - | $1.56 M(-5.4%) | $6.51 M(+0.9%) |
| Mar 2018 | - | $1.65 M(+7.9%) | $6.45 M(+0.6%) |
| Dec 2017 | $6.41 M(-43.7%) | $1.53 M(-13.8%) | $6.41 M(-19.0%) |
| Sept 2017 | - | $1.77 M(+18.2%) | $7.91 M(-9.6%) |
| June 2017 | - | $1.50 M(-6.8%) | $8.75 M(-13.2%) |
| Mar 2017 | - | $1.61 M(-46.8%) | $10.07 M(-11.5%) |
| Dec 2016 | $11.38 M(-2.4%) | $3.03 M(+16.0%) | $11.38 M(-3.0%) |
| Sept 2016 | - | $2.61 M(-7.6%) | $11.73 M(+1.1%) |
| June 2016 | - | $2.83 M(-3.2%) | $11.60 M(-5.2%) |
| Mar 2016 | - | $2.92 M(-13.6%) | $12.23 M(+4.9%) |
| Dec 2015 | $11.66 M(+53.4%) | $3.38 M(+36.3%) | $11.66 M(-3.3%) |
| Sept 2015 | - | $2.48 M(-28.4%) | $12.05 M(+12.9%) |
| June 2015 | - | $3.46 M(+47.5%) | $10.68 M(+25.5%) |
| Mar 2015 | - | $2.35 M(-37.8%) | $8.51 M(+12.0%) |
| Dec 2014 | $7.60 M(-37.7%) | $3.77 M(+241.7%) | $7.60 M(+4.2%) |
| Sept 2014 | - | $1.10 M(-14.6%) | $7.29 M(-18.1%) |
| June 2014 | - | $1.29 M(-10.0%) | $8.90 M(-9.9%) |
| Mar 2014 | - | $1.43 M(-58.6%) | $9.87 M(-19.1%) |
| Dec 2013 | $12.20 M(-15.9%) | $3.46 M(+27.6%) | $12.20 M(-24.1%) |
| Sept 2013 | - | $2.71 M(+19.6%) | $16.06 M(+9.5%) |
| June 2013 | - | $2.27 M(-39.7%) | $14.67 M(-12.6%) |
| Mar 2013 | - | $3.76 M(-48.7%) | $16.78 M(+15.7%) |
| Dec 2012 | $14.50 M(+45.1%) | $7.33 M(+456.7%) | $14.50 M(+44.8%) |
| Sept 2012 | - | $1.32 M(-69.9%) | $10.01 M(-7.6%) |
| June 2012 | - | $4.38 M(+194.9%) | $10.84 M(+22.0%) |
| Mar 2012 | - | $1.48 M(-47.7%) | $8.88 M(-11.1%) |
| Dec 2011 | $10.00 M(-5.9%) | $2.84 M(+32.7%) | $10.00 M(+3.1%) |
| Sept 2011 | - | $2.14 M(-11.7%) | $9.69 M(+6.1%) |
| June 2011 | - | $2.42 M(-6.7%) | $9.14 M(+3.7%) |
| Mar 2011 | - | $2.60 M(+2.4%) | $8.81 M(-17.1%) |
| Dec 2010 | $10.63 M | $2.54 M(+60.1%) | $10.63 M(-3.3%) |
| Sept 2010 | - | $1.58 M(-24.5%) | $10.99 M(+1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $2.10 M(-52.4%) | $10.80 M(-37.4%) |
| Mar 2010 | - | $4.41 M(+51.8%) | $17.24 M(+16.9%) |
| Dec 2009 | $14.73 M(+114.9%) | $2.90 M(+109.5%) | $14.75 M(+5.4%) |
| Sept 2009 | - | $1.39 M(-83.8%) | $14.00 M(-6.3%) |
| June 2009 | - | $8.54 M(+344.8%) | $14.93 M(+91.5%) |
| Mar 2009 | - | $1.92 M(-10.8%) | $7.80 M(+29.3%) |
| Dec 2008 | $6.85 M(+765.3%) | $2.15 M(-7.2%) | $6.03 M(-544.7%) |
| Sept 2008 | - | $2.32 M(+65.2%) | -$1.36 M(+347.5%) |
| June 2008 | - | $1.40 M(+817.6%) | -$303.00 K(-74.6%) |
| Mar 2008 | - | $153.00 K(-102.9%) | -$1.20 M(+11.9%) |
| Dec 2007 | $792.00 K(-90.0%) | -$5.23 M(-255.1%) | -$1.07 M(-109.7%) |
| Sept 2007 | - | $3.37 M(+558.8%) | $11.01 M(+41.7%) |
| June 2007 | - | $512.00 K(+82.9%) | $7.76 M(+0.8%) |
| Mar 2007 | - | $280.00 K(-95.9%) | $7.71 M(-2.8%) |
| Dec 2006 | $7.93 M(+32.0%) | $6.84 M(+5042.9%) | $7.93 M(+263.5%) |
| Sept 2006 | - | $133.00 K(-70.6%) | $2.18 M(-39.9%) |
| June 2006 | - | $453.00 K(-9.8%) | $3.63 M(-23.1%) |
| Mar 2006 | - | $502.00 K(-54.1%) | $4.72 M(-21.0%) |
| Dec 2005 | $6.00 M(-11.9%) | $1.09 M(-30.9%) | $5.97 M(-1.0%) |
| Sept 2005 | - | $1.58 M(+2.7%) | $6.03 M(-3.1%) |
| June 2005 | - | $1.54 M(-12.2%) | $6.22 M(+0.0%) |
| Mar 2005 | - | $1.75 M(+52.3%) | $6.22 M(-8.8%) |
| Dec 2004 | $6.82 M(-51.6%) | $1.15 M(-35.1%) | $6.82 M(-34.6%) |
| Sept 2004 | - | $1.77 M(+15.2%) | $10.43 M(-20.7%) |
| June 2004 | - | $1.54 M(-34.5%) | $13.15 M(-9.4%) |
| Mar 2004 | - | $2.35 M(-50.6%) | $14.51 M(+3.0%) |
| Dec 2003 | $14.09 M(+53.7%) | $4.76 M(+5.9%) | $14.09 M(+23.9%) |
| Sept 2003 | - | $4.50 M(+54.8%) | $11.37 M(+11.7%) |
| June 2003 | - | $2.90 M(+50.5%) | $10.18 M(+2.0%) |
| Mar 2003 | - | $1.93 M(-5.8%) | $9.98 M(+8.9%) |
| Dec 2002 | $9.17 M(+62.3%) | $2.05 M(-38.0%) | $9.17 M(+7.0%) |
| Sept 2002 | - | $3.30 M(+22.0%) | $8.57 M(+28.5%) |
| June 2002 | - | $2.71 M(+143.9%) | $6.67 M(+41.0%) |
| Mar 2002 | - | $1.11 M(-23.5%) | $4.73 M(+30.7%) |
| Dec 2001 | $5.65 M(-9.6%) | $1.45 M(+3.6%) | $3.62 M(+66.9%) |
| Sept 2001 | - | $1.40 M(+82.3%) | $2.17 M(+182.3%) |
| June 2001 | - | $768.00 K | $768.00 K |
| Dec 2000 | $6.25 M(+313.2%) | - | - |
| Dec 1999 | $1.51 M | - | - |
FAQ
- What is the all time high annual revenue for Plus Therapeutics?
- What is the all time high quarterly revenue for Plus Therapeutics?
- What is the all time high TTM revenue for Plus Therapeutics?
What is the all time high annual revenue for Plus Therapeutics?
Plus Therapeutics all-time high annual revenue is $14.73 M
What is the all time high quarterly revenue for Plus Therapeutics?
Plus Therapeutics all-time high quarterly revenue is $8.54 M
What is the all time high TTM revenue for Plus Therapeutics?
Plus Therapeutics all-time high TTM revenue is $17.24 M